Skip to main content Back to Top
Advertisement

12/11/2020

Ulipristal Acetate

Reason for the Shortage

    • HRA Pharma had Ella on shortage due to manufacturing delays.

Available Products

    • Ella tablet, HRA Pharma, 30 mg, single-dose packet, NDC 73302-0456-01

Estimated Resupply Dates

    • HRA Pharma has Ella available.

Alternative Agents & Management

    • The American College of Obstetrics and Gynecology (ACOG) clinical guidance for emergency contraception is available at: https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2015/09/emergency-contraception
    • Princeton has a list of specific emergency contraceptive products that was last updated at the end of August 2020. This list is available at https://ec.princeton.edu/questions/dose.html#dose
    • The copper intrauterine device is the most effective form of contraception per ACOG but requires an office visit to a provider and may not be desired or practical for some patients.
    Table 1. Oral Emergency Contraceptives (information from ACOG and Princeton)
    Oral Emergency Contraceptive (EC)Active IngredientFDA Approved for ECSecond Dose Needed
    Selective progesterone receptor modulatorUlipristal acetate YesNo
    Progestin onlyLevonorgestrel YesNo
    Combined progestin/estrogen Levonorgestrel/ethinyl estradiolNoYes

Updated

Updated December 11, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created September 15, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.

ADVERTISEMENT